Form 4: Recursion Pharmaceuticals CEO Exercises Stock Options, Acquires Shares
SEC Form 4 Filing
Christopher Gibson, CEO of Recursion Pharmaceuticals, exercised stock options to acquire 5,000 shares of Class A Common Stock at $2.48 per share on August 23, 2024.
Summary
- On August 23, 2024, Christopher Gibson, the CEO of Recursion Pharmaceuticals, exercised stock options to acquire 5,000 shares of Class A Common Stock.
- The transaction was executed at a price of $2.48 per share.
- Following the transaction, Gibson directly owns 737,656 shares of Class A Common Stock.
- Gibson also indirectly owns shares through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust.
- He also holds options to purchase additional shares of Class A Common Stock at various exercise prices and vesting schedules.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing detailing an insider transaction. The CEO exercising options could be seen as a slightly positive signal, but it's not a strong indicator of overall company performance.
Positives
- The CEO's decision to exercise stock options and increase his stake in the company could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives and their holdings in the company's stock.
Comparison to Industry Standards
- Insider transactions are a common occurrence in publicly traded companies, and the reporting requirements are standardized by the SEC.
- Comparing the CEO's ownership stake and option holdings to those of CEOs in similar biotech companies would provide a better understanding of the significance of these holdings.
- Companies like Amgen, Gilead Sciences, and Biogen are examples of large biotech companies where insider ownership and option grants are closely monitored.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment if investors view the CEO's increased stake as a sign of confidence.
Key Dates
| Date | Description |
|---|---|
| 01/31/2021 | Start date for vesting of options for 1,500,000 shares, vesting monthly thereafter. |
| 03/01/2022 | Start date for vesting of options for 416,350 shares, vesting monthly thereafter. |
| 03/01/2023 | Start date for vesting of options for 813,600 shares, vesting monthly thereafter. |
| 03/01/2024 | Start date for vesting of options for 666,898 shares, vesting monthly thereafter. |
| 08/23/2024 | Date of transaction: CEO exercised stock options to acquire 5,000 shares. |
| 12/30/2030 | Expiration date for some stock options. |
| 02/04/2032 | Expiration date for some stock options. |
| 02/01/2033 | Expiration date for some stock options. |
| 02/09/2034 | Expiration date for some stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.